This cohort study evaluated the association between changes in IHS4 (International Hidradenitis Suppurativa Severity Score System) scores and treatment with intravenous or subcutaneous golimumab in patients with moderate to severe, treatment-refractory hidradenitis suppurativa.
Abstract-only data available; specific outcomes, sample size, follow-up duration, and comparator details are not reported.
Golimumab (IV and SC) is being explored as an option for treatment-refractory moderate-to-severe HS; clinicians should await full study data before adopting this into routine practice.
Explore related topics
